

Claims

This listing of the claims will replace all prior versions:

1. (previously presented) An isolated and purified peptide which blocks the binding of an anti-HLA class II antibody to a cell expressing HLA class II antigen and is capable of eliciting antibodies reactive against HLA class II antigen, wherein the sequence of the peptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

2. (canceled)

3. (currently amended) The peptide of claim 2 1 wherein the sequence of the peptide is SEQ ID NO:1.

4. (currently amended) The peptide of claim 2 1 wherein the sequence of the peptide is SEQ ID NO:5.

5. (withdrawn) A method for eliciting antibodies against HLA class II antigen in an individual comprising the steps of administering to the individual an effective amount of a HLA class II antigen peptide mimic, wherein said peptide mimic elicits antibodies to HLA class II antigen in the individual.

6. (withdrawn) The method of claim 5, wherein the peptide has a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8 and combinations thereof.

Serial No.: 10/804,392

January 8, 2009

Page 3 of 6

7. (withdrawn) The method of claim 5, wherein the peptide has a sequence of SEQ ID NO:1.

8. (withdrawn) The method of claim 5, wherein the peptide has a sequence SEQ ID NO:5.

9. (withdrawn) The method of claim 5, wherein the individual has NHL.

10. (withdrawn) The method of claim 5, wherein the peptide mimic is administered in conjunction with radiation therapy.

11. (withdrawn) The method of claim 5, wherein the peptide mimic is administered in conjunction with chemotherapy.

12. - 14. (canceled)

15. (currently amended) The antigenic composition of claim ~~42~~ 18, wherein the peptide consists of a sequence of SEQ ID NO:1.

16. (currently amended) The antigenic composition of claim ~~42~~ 18, wherein the peptide consists of a sequence of SEQ ID NO:5.

17. (canceled)

18. (new) An antigenic composition comprising a pharmaceutically acceptable carrier and a peptide which blocks the binding of an anti-HLA class II antibody to a cell bearing HLA class II antigen and is capable of eliciting antibodies reactive against HLA class II antigen, wherein the

Serial No.: 10/804,392

January 8, 2009

Page 4 of 6

peptide consists of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.